Last reviewed · How we verify
DS-6051b
At a glance
| Generic name | DS-6051b |
|---|---|
| Sponsor | Daiichi Sankyo Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene (PHASE2)
- Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (PHASE2)
- Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
- Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases
- A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b (PHASE1)
- Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) (PHASE2)
- Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DS-6051b CI brief — competitive landscape report
- DS-6051b updates RSS · CI watch RSS
- Daiichi Sankyo Co., Ltd. portfolio CI